EMA Authorised: Palsonify (paltusotine hydrochloride) — Crinetics Pharmaceuticals Europe GmbH

View source ↗

Summary

Palsonify (paltusotine hydrochloride) has been authorised in Europe for acromegaly, with Crinetics Pharmaceuticals Europe GmbH as the MAH and orphan designation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• PALSONIFY (PALTUSOTINE)

Snippet

Status: Authorised. Therapeutic area: Acromegaly. MAH: Crinetics Pharmaceuticals Europe GmbH. Decision date: 15/06/2026. Orphan medicine